Pretransplant Characteristics and BMT Protocols Adopted in 111 Children Treated With Allogeneic BMT
| . | No. Patients (%) . |
|---|---|
| Underlying disease: | |
| ALL | 68 (61) |
| AML | 22 (20) |
| JCML | 2 (2) |
| CML | 7 (6) |
| SAA | 4 (4) |
| RAEB | 7 (6) |
| Histiocytosis X | 1 (1) |
| Disease status at BMT: | |
| 1° CR | 22 (20) |
| 2° CR | 55 (49.5) |
| >2° CR | 6 (5.5) |
| Chronic phase | 7 (6) |
| Relapse/resistant/blastic transformation | 17 (15) |
| SAA | 4 (4) |
| Conditioning regimen: | |
| Cy + fTBI | 16 (14) |
| Cy + HDARAC + fTBI | 14 (13) |
| Cy + VCR + fTBI | 46 (41) |
| Cy + VP16 + fTBI | 15 (13.5) |
| Cy + BU | 11 (10) |
| Cy + BU + melphalan | 5 (4.5) |
| Cy | 4 (4) |
| GVHD prophylaxis: | |
| CSA | 101 (91) |
| CSA + MTX | 8 (7) |
| None | 2 (2) |
| Antiviral prophylaxis: | |
| Acyclovir | 83 (75) |
| Foscarnet | 7 (6) |
| None | 21 (19) |
| . | No. Patients (%) . |
|---|---|
| Underlying disease: | |
| ALL | 68 (61) |
| AML | 22 (20) |
| JCML | 2 (2) |
| CML | 7 (6) |
| SAA | 4 (4) |
| RAEB | 7 (6) |
| Histiocytosis X | 1 (1) |
| Disease status at BMT: | |
| 1° CR | 22 (20) |
| 2° CR | 55 (49.5) |
| >2° CR | 6 (5.5) |
| Chronic phase | 7 (6) |
| Relapse/resistant/blastic transformation | 17 (15) |
| SAA | 4 (4) |
| Conditioning regimen: | |
| Cy + fTBI | 16 (14) |
| Cy + HDARAC + fTBI | 14 (13) |
| Cy + VCR + fTBI | 46 (41) |
| Cy + VP16 + fTBI | 15 (13.5) |
| Cy + BU | 11 (10) |
| Cy + BU + melphalan | 5 (4.5) |
| Cy | 4 (4) |
| GVHD prophylaxis: | |
| CSA | 101 (91) |
| CSA + MTX | 8 (7) |
| None | 2 (2) |
| Antiviral prophylaxis: | |
| Acyclovir | 83 (75) |
| Foscarnet | 7 (6) |
| None | 21 (19) |
Abbreviations: CR, complete remission; CY, cyclophosphamide; HDARAC, high-dose Ara-C; VCR, vincristine; VP16, etoposide; BU, busulphan; fTBI, fractionated total body irradiation; CSA, cyclosporin; MTX, methotrexate.